{"id":8840,"date":"2025-06-26T06:16:52","date_gmt":"2025-06-26T11:16:52","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=8840"},"modified":"2025-07-13T15:08:42","modified_gmt":"2025-07-13T20:08:42","slug":"nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","title":{"rendered":"Nanoscope Therapeutics impulsa la innovaci\u00f3n centrada en el paciente en enfermedades retinianas hereditarias con un nuevo comit\u00e9 asesor visionario."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"8840\" class=\"elementor elementor-8840\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-65279c3f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"65279c3f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4b40c268\" data-id=\"4b40c268\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-76485331 elementor-widget elementor-widget-text-editor\" data-id=\"76485331\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><div class=\"col-sm-8 col-vcenter col-xs-12\"><h3 style=\"text-align: center;\">\u00a0<\/h3><\/div><div class=\"col-sm-4 col-xs-12 col-vcenter\"><div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\"><p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">26 de junio de 2025 <\/span><\/span>\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas independientes para pacientes que sufren una p\u00e9rdida grave de la visi\u00f3n debido a enfermedades degenerativas de la retina, anunci\u00f3 hoy la formaci\u00f3n de su\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">Comit\u00e9 Asesor Visionario (VAC)<\/a>\u00a0\u2013 un grupo de expertos de renombre en el tratamiento y la comercializaci\u00f3n de la retina.<\/p><p class=\"prntaj\">El VAC funcionar\u00e1 como un equipo estrat\u00e9gico y alineado con la misi\u00f3n, que informar\u00e1 los esfuerzos cient\u00edficos, cl\u00ednicos y comunitarios de Nanoscope.\u00a0<b><i>Su misi\u00f3n: mejorar la atenci\u00f3n a los pacientes, fomentar una colaboraci\u00f3n aut\u00e9ntica con los m\u00e9dicos y ayudar a trazar el camino para ofrecer una terapia transformadora, en primer lugar, a las personas que viven con retinosis pigmentaria (RP) y enfermedad de Stargardt (SD).<\/i><\/b><\/p><p class=\"prntaj\">\u201cEsto es m\u00e1s que un simple comit\u00e9: representa una clara declaraci\u00f3n de nuestro compromiso inquebrantable con los pacientes a los que servimos y la misi\u00f3n en la que creemos\u201d, dijo.\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, cofundador y director ejecutivo de Nanoscope Therapeutics. \u201cEn Nanoscope estamos construyendo el futuro del cuidado de la retina con los ojos bien abiertos, guiados por aquellos que realmente comprenden la vida de los pacientes a los que nos comprometemos a ayudar\u201d.\u201d<\/p><p class=\"prntaj\">MCO-010 es la terapia optogen\u00e9tica m\u00e1s avanzada en fase cl\u00ednica en desarrollo para la retinosis pigmentaria. Utilizando la opsina multicaracter\u00edstica (MCO) patentada por Nanoscope, MCO-010 es la primera terapia optogen\u00e9tica experimental que ha demostrado una posible restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida visual grave en ensayos cl\u00ednicos.<\/p><p class=\"prntaj\">\u201cLo que distingue a MCO-010 no son solo sus avances cient\u00edficos, sino tambi\u00e9n su accesibilidad en la pr\u00e1ctica\u201d, a\u00f1adi\u00f3 Bhattacharya. \u201cEst\u00e1 dise\u00f1ado para administrarse mediante una \u00fanica inyecci\u00f3n en la consulta, sin necesidad de pruebas gen\u00e9ticas, cirug\u00eda ni mantenimiento continuo\u201d.\u201d<\/p><p>El\u00a0<b>El Comit\u00e9 de Vigilancia Vecinal estar\u00e1 presidido por SriniVas Sadda, MD.<\/b>., la A.\u00a0<span class=\"xn-person\">Ray Irvine, Jr.<\/span>, Doctor en Medicina, C\u00e1tedra de Oftalmolog\u00eda Cl\u00ednica y Profesor en la\u00a0<span class=\"xn-org\">Universidad de California, Los \u00c1ngeles<\/span>\u00a0Facultad de Medicina David Geffen e Instituto Oftalmol\u00f3gico Doheny.<\/p><p class=\"prntaj\">\u201cComo especialistas en retina, tenemos la imperiosa necesidad de cambiar la conversaci\u00f3n que tenemos con nuestros pacientes sobre la ceguera, pasando de considerarla inevitable a verla como una posibilidad\u201d, afirm\u00f3 el Dr. Sadda. \u201cMe siento honrado de formar parte de un equipo que cree que el statu quo no es inmutable y que la recuperaci\u00f3n de la visi\u00f3n no es un sue\u00f1o, sino una meta alcanzable\u201d.\u201d<\/p><p>Adem\u00e1s del Dr. Sadda, entre los miembros del VAC se encuentran:<\/p><ul type=\"disc\"><li><b><span class=\"xn-person\">Allen Ho<\/span>, m\u00e9dico,\u00a0<\/b>Profesor de Oftalmolog\u00eda,\u00a0<span class=\"xn-org\">Universidad Thomas Jefferson<\/span>\u00a0y Director de Investigaci\u00f3n de Retina, Wills Eye Hospital. Asesor M\u00e9dico Jefe de Nanoscope Therapeutics.<\/li><li><b><span class=\"xn-person\">Peter K\u00e1iser<\/span>, m\u00e9dico,\u00a0<\/b>Profesor de Oftalmolog\u00eda, Facultad de Medicina Lerner de la Cl\u00ednica Cleveland y C\u00e1tedra Chaney de Investigaci\u00f3n en Oftalmolog\u00eda, Instituto Oftalmol\u00f3gico Cole.<\/li><li><b><span class=\"xn-person\">Christine Kay<\/span>, MD<\/b>., Director de Investigaci\u00f3n Cl\u00ednica y Gen\u00e9tica Retiniana, Vitreoretinal Associates en\u00a0<span class=\"xn-location\">Gainesville<\/span><\/li><li><b><span class=\"xn-person\">Arshad Khanani<\/span>, Doctor en Medicina, M\u00e1ster en Artes,\u00a0<\/b>Profesor Cl\u00ednico,\u00a0<span class=\"xn-org\">Universidad de Nevada, Reno<\/span>\u00a0Facultad de Medicina y Director de Investigaci\u00f3n Cl\u00ednica, Sierra Eye Associates<\/li><li><b><span class=\"xn-person\">Vinit Mahajan<\/span>, Doctor en Medicina, Doctor en Filosof\u00eda,\u00a0<\/b>Profesor de Oftalmolog\u00eda,\u00a0<span class=\"xn-org\">Universidad Stanford<\/span>\u00a0y Vicepresidente de Investigaci\u00f3n y Director del Programa de Cirug\u00eda Molecular del Instituto Oftalmol\u00f3gico Byers.<\/li><li><b>Jordi Mon\u00e9s, Doctor en Medicina, Doctor en Filosof\u00eda,\u00a0<\/b>Director, Instituto de la M\u00e1cula,\u00a0<span class=\"xn-location\">Barcelona<\/span><\/li><li><b><span class=\"xn-person\">Mark Pennesi<\/span>, Doctor en Medicina, Doctor en Filosof\u00eda,\u00a0<\/b>Profesor adjunto de Oftalmolog\u00eda del Instituto Oftalmol\u00f3gico Casey de la Universidad de Salud y Ciencias de Oreg\u00f3n y director de la Divisi\u00f3n de Degeneraciones Retinianas Hereditarias de la Fundaci\u00f3n Retina.<\/li><\/ul><p>Para ver las biograf\u00edas completas, visite:\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/who-we-are\/#vac\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanostherapeutics.com\/who-we-are\/#vac<\/a><\/p><p class=\"prntaj\">La creaci\u00f3n de VAC refleja la convicci\u00f3n de Nanoscope de que brindar innovaciones significativas a los pacientes comienza con la colaboraci\u00f3n y contin\u00faa con la acci\u00f3n, para devolver la esperanza a millones de pacientes en todo el mundo que sufren degeneraci\u00f3n retiniana.<\/p><p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica independiente del gen que restaura la visi\u00f3n para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos de la fase RESTORE\u00a0<span class=\"xn-money\">2b<\/span>\/3 Ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la retinosis pigmentaria (RP) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se planea que comience una presentaci\u00f3n continua de BLA ante la FDA en\u00a0<span class=\"xn-chron\">Junio de 2025<\/span>. Si se aprueba, MCO-010 tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planes para iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0En 2025, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD. Los programas precl\u00ednicos incluyen amaurosis cong\u00e9nita de Leber (LCA), en estudios precl\u00ednicos, as\u00ed como un f\u00e1rmaco listo para la solicitud de IND para atrofia geogr\u00e1fica (GA).<\/p><p><b>Contacto:<\/b><br class=\"dnr\" \/>Terap\u00e9utica del nanoscopio<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p><\/div><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a0 DALLAS,\u00a0June 26, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from\u00a0retinal degenerative diseases, today announced the formation of its\u00a0Visionary Advisory Committee (VAC)\u00a0\u2013 a group of renowned experts in retina treatment and commercialization. The VAC will serve as a strategic and mission-aligned [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8841,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-8840","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-26T11:16:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"},\"wordCount\":727,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\",\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"datePublished\":\"2025-06-26T11:16:52+00:00\",\"dateModified\":\"2025-07-13T20:08:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/06\\\/26\\\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics impulsa la innovaci\u00f3n centrada en el paciente en enfermedades retinianas hereditarias con un nuevo comit\u00e9 asesor visionario - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-06-26T11:16:52+00:00","article_modified_time":"2025-07-13T20:08:42+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"},"wordCount":727,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","url":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/","name":"Nanoscope Therapeutics impulsa la innovaci\u00f3n centrada en el paciente en enfermedades retinianas hereditarias con un nuevo comit\u00e9 asesor visionario - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","datePublished":"2025-06-26T11:16:52+00:00","dateModified":"2025-07-13T20:08:42+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_25-LI_VAC-V2_White_REV4.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/06\/26\/nanoscope-therapeutics-propels-patient-centered-innovation-in-inherited-retinal-diseases-with-new-visionary-advisory-committee\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/8840","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=8840"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/8840\/revisions"}],"predecessor-version":[{"id":9068,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/8840\/revisions\/9068"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/8841"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=8840"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=8840"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=8840"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}